A rare case of Epstein–Barr virus-positive mucocutaneous ulcer that developed into an intestinal obstruction: a case report

Table 2 Summary of reported cases of EBV-MCU associated with gastrointestinal tract involvement

Case	Age	Sex	Lesion location	Comorbidity	Risk factor	Treatment	Outcome	Ref
1	69	F	Colon	RA	MTX	ND	ND	2
2	53	F	Colon, Rectum	CD	MTX, Infliximab	Dose reduction	Development of HL	7
3	75	F	Esophagus	RA	AZA	Dose reduction	Improvement	2
4	63	M	Anus	CD	AZA	Dose reduction	Improvement	5
5	81	F	Colon	ITP	AZA	Surgical resection	Death by LPD	3
6	26	M	Rectum	CD	AZA, Infliximab	Surgical resection	Improvement	12
7	78	M	Rectum	UC	CyA	Dose reduction	Improvement	2
8	64	F	Colon	HSCT	CyA	Dose reduction	Improvement	2
9	61	M	Esophagus	Organ transplant	MMF	Dose reduction	Improvement	4
10	70	M	Rectum	Organ transplant	MMF	Dose reduction, Rituximab adm	Improvement	4
11	32	M	Terminal ileum	Organ transplant	MMF, Tac	Dose reduction, Rituximab adm	Improvement	4
12	61	F	Esophagus	PID	immune deficiency	Rituximab adm, IVIG adm	No change	6
13	64	F	Cecum	None	Age	Surgical resection	Improvement	11
14	81	M	Colon	CKD	Age	Surgical resection	Improvement	Our case

Abbreviations; adm administration; AZA azathioprine; CD crohn’s disease; CKD chronic kidney disease; CyA cyclosporine; EBV-MCU Epstein Barr virus-positive mucocutaneous ulcer; F female; HL Hodgkin’s lymphoma; HSCT hematopoietic stem cell transplantation; ITP idiopathic thrombocytopenic purpura; IVIG intravenous immunoglobulin; LPD lymphoproliferative disease; M male; MMF mycophenolate mofetil; MTX methotrexate; ND not described; PID primary immnodeficiency disease; RA rheumatoid arthritis, Ref reference; Tac tacrolimus; UC ulcerative colitis

ISSN: 1471-230X